Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ:BMRN
Want to see BMRN full AI Analyst Report?
BMRN Stock Chart & Stats
$54.64
$0.93(1.37%)
At close: 4:00 PM EST
$54.64
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$49.26 - $66.28
Previous CloseN/A
Volume465.01K
Average Volume (3M)2.39M
Market Cap
$10.81B
Enterprise Value$10.29B
Total Cash (Recent Filing)$2.22B
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)40.1
Beta0.54
Next Earnings
Aug 04, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.40
Shares Outstanding193,284,440
10 Day Avg. Volume2,167,351
30 Day Avg. Volume2,392,070
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda21.33
Forecast
1Y Price Target
$87.00Price Target Upside59.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)4.94
Revenue Forecast (FY)$3.90B
Bulls Say, Bears Say
Bulls Say
Expanded Rare-disease Portfolio (Amicus)Acquiring Amicus materially broadens BioMarin’s product set across lysosomal storage diseases, adding an oral Fabry therapy and Pompe assets with established sales; this diversifies revenue streams, increases cross‑sell and lifecycle opportunities, and meaningfully raises medium‑term growth potential.
Upgraded 2026 Guidance & Revenue MomentumManagement raised 2026 top‑line guidance driven by enzyme therapies and Amicus inclusion, reflecting accelerating patient demand and commercial scale. Sustained guidance uplift signals durable revenue growth capacity and supports reinvestment in pipeline and global commercialization over the next 2–3 years.
Strong Cash Generation & Improving Balance SheetOperating and free cash flow strengthened materially in 2024 and TTM, and equity has built over time. Robust cash generation supports R&D, integration spending, and debt service, giving management flexibility to fund pipeline advancement and absorb near‑term acquisition-related costs.
Bears Say
Margin Compression & Rising OpexMargins have meaningfully compressed despite revenue growth as R&D and SG&A increased to support multiple programs and commercial expansion. Persistent cost pressure can erode operating leverage, constrain free cash flow conversion, and delay the timeline for acquisition synergies to restore prior profitability levels.
Higher Leverage From Acquisition FinancingThe Amicus deal added substantial asset‑backed, covenant‑heavy financing and increased total debt versus 2025. Elevated leverage raises refinancing and covenant risk, reduces financial flexibility for opportunistic spending, and increases sensitivity to cash‑flow variability over the next 12–24 months.
Clinical, Regulatory And Legal UncertaintyA partial halt of VOXZOGO dosing and pending ITC litigation introduce execution risk to label expansion and IP protection. These issues can delay approvals, constrain market access for new indications, and create downside scenarios for projected peak sales if safety, regulatory or legal outcomes are unfavorable.
BioMarin Pharmaceutical News
BMRN FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was $49.26 and its highest was $66.28 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is $10.81B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 51 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on May 04, 2026. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.692 by $0.068.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.95.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 193,284,440 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of $0.76 in its last earnings report, beating expectations of $0.692. Following the earnings report the stock price went down -4.003%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in BMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.00 (59.22% Upside)
$87.00 (59.22% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $176.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.32%
12-Months-Change
Fundamentals
Return on Equity
4.41%
Trailing 12-Months
Asset Growth
20.20%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by the recent Amicus acquisition, upgraded 2026 revenue guidance (~20% total revenue growth and ~30% Enzyme Therapies growth at midpoint), strong underlying patient demand (Voxzogo patients +20% y/y; Enzyme Therapies +6% y/y), and multiple near‑term clinical catalysts. Near‑term softness in reported Q1 revenue, a $31M one‑time manufacturing charge, higher operating expenses and modest 2026 EPS dilution are notable headwinds, but management attributes much of the revenue softness to order timing and positions acquisition dilution as temporary with accretion expected within 12 months and substantial accretion in 2027. Overall, the positives (deal, guidance lift, patient growth, pipeline milestones) outweigh the one‑time charges and timing issues.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$87.00
▲(59.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.46% Insiders
31.88% Mutual Funds
36.55% Other Institutional Investors
9.87% Public Companies and
Individual Investors